Candel Therapeutics, Inc. (CADL) Reports Q2 Loss of $0.74/sh

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q2 EPS of ($0.74), versus ($0.33) reported last year.

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Deutsche Bank Reiterates Buy Rating on Volkswagen AG (VOW:GR) (VWAGY)
• Faraday Future unveils nine robot models, prices start at $9,990
• Rothschild Redburn Starts Z AI Co Ltd (2513:HK) at Buy